Compare TAYD & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | BNR |
|---|---|---|
| Founded | 1955 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.0M | 216.9M |
| IPO Year | N/A | 2020 |
| Metric | TAYD | BNR |
|---|---|---|
| Price | $83.23 | $32.80 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $70.00 | N/A |
| AVG Volume (30 Days) | ★ 43.7K | 24.5K |
| Earning Date | 03-27-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.18 | N/A |
| EPS | ★ 3.01 | N/A |
| Revenue | $47,647,810.00 | ★ $75,749,382.00 |
| Revenue This Year | $10.81 | $136.32 |
| Revenue Next Year | $8.37 | N/A |
| P/E Ratio | $27.80 | ★ N/A |
| Revenue Growth | ★ 7.11 | 5.56 |
| 52 Week Low | $29.50 | $2.18 |
| 52 Week High | $86.00 | $41.72 |
| Indicator | TAYD | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 80.77 | 51.13 |
| Support Level | $69.31 | $29.50 |
| Resistance Level | $86.00 | $34.26 |
| Average True Range (ATR) | 3.12 | 4.10 |
| MACD | 0.55 | -0.95 |
| Stochastic Oscillator | 88.92 | 12.56 |
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.